跳转至内容
Merck
所有图片(1)

文件

565790

Sigma-Aldrich

Compound E

≥95% (HPLC), solid, γ-secretase inhibitor, Calbiochem®

别名:

γ-分泌酶抑制剂XXI,化合物E

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C27H24F2N4O3
分子量:
490.50
分類程式碼代碼:
12352200
NACRES:
NA.77

product name

γ-分泌酶抑制剂XXI,化合物E, This g-secretase inhibitor, CAS 209986-17-4, is a cell-permeable, potent, selective, non-transition-state analog inhibitor of γ-secretase and Notch processing. Lowers Aβ levels in APP transgenic mice

化驗

≥95% (HPLC)

形狀

solid

製造商/商標名

Calbiochem®

儲存條件

OK to freeze
protect from light

顏色

white

溶解度

DMSO: 10 mg/mL

運輸包裝

ambient

儲存溫度

2-8°C

InChI

1S/C27H24F2N4O3/c1-16(30-23(34)14-17-12-19(28)15-20(29)13-17)26(35)32-25-27(36)33(2)22-11-7-6-10-21(22)24(31-25)18-8-4-3-5-9-18/h3-13,15-16,25H,14H2,1-2H3,(H,30,34)(H,32,35)/t16-,25?/m0/s1

InChI 密鑰

JNGZXGGOCLZBFB-YPHZTSLFSA-N

一般說明

γ-分泌酶和Notch加工的一种细胞可渗透的、有效的、选择性的、拟肽的、非过渡态类似物抑制剂(在过表达野生型βAPP的CHO细胞中,Aβ40的IC50为300 pM;在用βAPP695和mNotchΔE(M1727V)稳定转染的HEK293细胞中,Aβ40、Aβ42、NICD的IC50分别为240 pM、370 pM、320 pM;在SPA4CT稳定转染的SH-SY5Y细胞中,Aβ40和Aβ42的IC50为100 pM)在几个APP转基因小鼠模型中降低Aβ水平。据报道,与早老素结合并抑制跨膜蛋白底物的蛋白水解裂解,包括APLP1和APLP2、CD44、ErbB4、E-钙粘蛋白、低密度脂蛋白受体相关蛋白、Notch配体和p75NTR。在更高浓度(200-400 µM)下,对早老酶活性的影响很弱。

生化/生理作用

主要靶标
过表达野生型bAPP的CHO细胞中的γ-分泌酶和Notch加工Ab40
产物不与ATP竞争。
可逆:否
细胞可渗透性:是
靶标IC50:在过表达野生型βAPP的CHO细胞中,对于Aβ40,为300 pM;在用βAPP695和mNotchΔE(M1727V)稳定转染的HEK293细胞中,对于Aβ40、Aβ42、NICD,分别为240 pM、370 pM、320 pM;对于Aβ40为100 pM

包裝

用惰性气体包装

警告

毒性:标准处理(A)

重構

复溶后,等分并冷冻保存(-20°C)。贮备溶液在-20°C下可稳定保存至多6个月。

其他說明

Milano, J., et al. 2004.Toxicol.Sci.82, 341.
Jung, K.M., et al. 2003.J. Biol. Chem.278, 42161.
Murakami, D., et al. 2003.Oncogene22, 1511.
Campbell, W.A., et al. 2003.J. Neurochem.85, 1563.
Berechid, B.E., et al., 2002.J. Biol. Chem.277, 8154.
Lee, H.J., et al. 2002.J. Biol. Chem.277, 6318.
May, P., et al. 2002.J. Biol. Chem.277, 18736.
Scheinfeld, M.H., et al. 2002.J. Biol. Chem.277, 44195.
Ni, C. Y., et al. 2001.Science294, 2179.
Beher, D., et al. 2001.J. Biol. Chem.276, 45394.
Doerfler, P., et al. 2001.Proc.Natl.Acad.Sci. USA98, 9312.
Seiffert, D., et al. 2000.J. Biol. Chem.275, 34086.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Kenichi Makino et al.
Journal for immunotherapy of cancer, 10(1) (2022-02-02)
Dendritic cells (DCs) play critical roles in regulating the innate and adaptive immune responses, and have long been a major focus of cancer immunotherapy. Accumulating evidence suggests that conventional type 1 DCs (cDC1s) excel in cross-presentation of exogenous antigens on
Louise Thiry et al.
ASN neuro, 14, 17590914211073381-17590914211073381 (2022-01-14)
Human induced pluripotent stem cells (hiPSCs) derived from healthy and diseased individuals can give rise to many cell types, facilitating the study of mechanisms of development, human disease modeling, and early drug target validation. In this context, experimental model systems
Claire E McGhee et al.
ACS central science, 7(11), 1809-1820 (2021-11-30)
Lithium has been a drug for bipolar disorders (BD) for over 70 years; however, its usage has been limited by its narrow therapeutic window (between 0.6 and 1.2 mM). Understanding the cellular distribution of lithium ions (Li+) in patient cells
Deli Hong et al.
Cancer research, 82(2), 248-263 (2021-11-24)
Neuroendocrine to nonneuroendocrine plasticity supports small cell lung cancer (SCLC) tumorigenesis and promotes immunogenicity. Approximately 20% to 25% of SCLCs harbor loss-of-function (LOF) NOTCH mutations. Previous studies demonstrated that NOTCH functions as a SCLC tumor suppressor, but can also drive
Christine E Eyler et al.
Genome biology, 21(1), 174-174 (2020-07-17)
Tumors can evolve and adapt to therapeutic pressure by acquiring genetic and epigenetic alterations that may be transient or stable. A precise understanding of how such events contribute to intratumoral heterogeneity, dynamic subpopulations, and overall tumor fitness will require experimental

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门